Table 5 Summary of pralatrexate in relapsed or refractory peripheral T-cell lymphoma.

From: Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis

StudyPhaseNo. of ptsMedian age
(range)
Line of pralatrexate
(≥4th line)
ORR (%)CR
(%)
PFS
(months)
Grade 3/4
hematological toxicities
Grade 3/4
mucositis
PROPEL15Prospective Ph. II11158 (21–85)Median prior CTx 3
(range, 1–13)
29%11%3.5Neutropenia 22%
Thrombocytopenia 33%
Anemia 18%
22%
Japanese18Prospective Ph. I/II2571 (42–83)52%45%32%5.0Neutropenia 24%
Thrombocytopenia 40%
Anemia 20%
20%
Chinese17Prospective Ph. II7156 (22–77)43%52%24%4.8Neutropenia 18%
Thrombocytopenia 20%
Anemia 24%
20%
KoreanRetrospective3858 (29–80)55%21%8%1.8Neutropenia 24%
Thrombocytopenia 34%
Anemia 18%
13%